Pharmacokinetic and relative bioavailability studies of cimoxatone in humansROVEI, V; MITCHARD, M; STROLIN BENEDETTI, M et al.International journal of clinical pharmacology, therapy and toxicology (1980). 1984, Vol 22, Num 1, pp 56-62, issn 0174-4879Article

CIMOXATONE IS A REVERSIBLE TIGHT-BINDING INHIBITOR OF THE A FORM OF RAT BRAIN MONOAMINE OXIDASEFOWLER CJ; STROLIN BENEDETTI M.1983; JOURNAL OF NEUROCHEMISTRY; ISSN 0022-3042; GBR; DA. 1983; VOL. 40; NO 2; PP. 510-513; BIBL. 13 REF.Article

THE METABOLISM OF DOPAMINE BY BOTH FORMS OF MONOAMINE OXIDASE IN THE RAT BRAIN AND ITS INHIBITION BY CIMOXATONEFOWLER CJ; BENEDETTI MS.1983; JOURNAL OF NEUROCHEMISTRY; ISSN 0022-3042; GBR; DA. 1983; VOL. 40; NO 6; PP. 1534-1541; BIBL. 2 P.Article

High-performance liquid chromatographic determination of cimoxatone and its O-demethyl metabolite in plasmaROVEI, V; RIGAL, M; SANJUAN, M et al.Journal of chromatography. 1983, Vol 277, pp 391-395, issn 0021-9673Article

Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidaseDOLLERY, C. T; BROWN, M. J; DAVIES, D. S et al.Clinical pharmacology and therapeutics. 1983, Vol 34, Num 5, pp 651-662, issn 0009-9236Article

Estimation of the elimination half-life of the monoamine oxidase inhibitor cimoxatone in rat brain on the basis of ex vivo inhibition dataFOWLER, C. J; STROLIN BENEDETTI, M; ROVEI, V et al.European journal of drug metabolism and pharmacokinetics. 1983, Vol 8, Num 4, pp 389-393, issn 0378-7966Article